Time to peak plasma concentration for short-acting opioids
| Drug and formulation . | Population . | Tmax (h) . |
|---|---|---|
| IV morphine (5 mg) | Healthy adults | 0.03 |
| Oral morphine liquid (10 mg) | Healthy adults | 0.75 |
| Intranasal diamorphine (1 mg/kg) | Children with isolated limb fracture | 0.17 |
| Oral oxycodone liquid (10-20 mg) | Healthy adults | <1.0 |
| Sublingual fentanyl (Abstral) | Opioid-tolerant cancer patients | 0.3-2 |
| Buccal fentanyl lozenge (Actiq; 800 μg) | Healthy adults | 1.5 |
| Buccal fentanyl effervescent tablet (Effentora; 400 μg) | Healthy adults | 0.78 |
| Drug and formulation . | Population . | Tmax (h) . |
|---|---|---|
| IV morphine (5 mg) | Healthy adults | 0.03 |
| Oral morphine liquid (10 mg) | Healthy adults | 0.75 |
| Intranasal diamorphine (1 mg/kg) | Children with isolated limb fracture | 0.17 |
| Oral oxycodone liquid (10-20 mg) | Healthy adults | <1.0 |
| Sublingual fentanyl (Abstral) | Opioid-tolerant cancer patients | 0.3-2 |
| Buccal fentanyl lozenge (Actiq; 800 μg) | Healthy adults | 1.5 |
| Buccal fentanyl effervescent tablet (Effentora; 400 μg) | Healthy adults | 0.78 |
Adapted from Telfer et al48 with permission.
Tmax, time to peak plasma concentration.